Briefing
ASCO GU 2026 proof-of-concept series links ctDNA to disease status in marker-negative germ cell tumors
An ASCO GU 2026 proof-of-concept series of 33 ctDNA samples from 21 patients with germ cell tumors, most of them marker-negative, reported 100% concordance between ctDNA detection and radiologic or pathologic disease status across the treatment phases assessed.